AOBO Announces New Product Launch
NEW YORK, Aug. 7 /PRNewswire-Asia-FirstCall/ -- - Jingwei Capsules Treat Allergy Symptoms - - Complements Established Boke Nasal Spray Brand - - Diversifies Product Offering with Capsule Formulation -
American Oriental Bioengineering, Inc. (NYSE: AOB), (“the Company” or
“AOBO”), a pharmaceutical company dedicated to improving health through the
development, manufacture and commercialization of a broad range of
prescription and over the counter (“OTC”) products in
that the Company has launched a new product for the rhinitis and allergy
market, called Jingwei Capsules (“Jingwei”). Jingwei will be manufactured by
the Company’s Boke subsidiary, and will be marketed throughout
AOBO’s distribution network, including the Company’s national hospital and
pharmacy distribution network.
Jingwei is an effective, long-lasting, tricyclic antihistamine that
selectively antagonizes peripheral H1-receptors. This unique mechanism
enables Jingwei to quickly alleviate the symptoms associated with rhinitis,
chronic urticaria, itching skin and other allergic skin reactions, but without
the common antihistamine side-effects. A branded version of Loratadine,
Jingwei is currently reimbursable under
Bioengineering, commented, “We are very pleased to be launching the Jingwei
Capsule, which is complementary to our market-leading Boke nasal spray. Its
major competitor is Schering-Plough’s Claritine, whose revenue is estimated to
effective and safe. With AOBO’s well-established distribution network, and
the strength of the Boke brand, we believe that the Jingwei capsule could
become one of AOBO’s leading products over time. We are confident in our
future growth prospects as we continue to expand our product lines and launch
innovative new products.”
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a pharmaceutical company
dedicated to improving health through the development, manufacture and
commercialization of a broad range of prescription and over the counter
Statements made in this press release are forward-looking and are made
pursuant to the safe harbor provisions of the Securities Litigation Reform Act
of 1995. Such statements involve risks and uncertainties that may cause
actual results to differ materially from those set forth in these statements.
The economic, competitive, governmental, technological and other factors
identified in the Company’s filings with the Securities and Exchange
Commission, including the Form 10-K for the year ended
cause actual results or events to differ materially from those described in
the forward looking statements in this press release. The Company undertakes
no obligation to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
SOURCE American Oriental Bioengineering, Inc.